WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HALO

Based on 7 analysts offering 12 month price targets for Halozyme Therapeutics Inc

Min Forecast
$65.00-0.29%
Avg Forecast
$76.29+17.02%
Max Forecast
$90.00+38.06%

Should I buy or sell HALO stock?

Based on 7 analysts offering ratings for Halozyme Therapeutics Inc.

Buy
Strong Buy
2 analysts 28.57%
Buy
2 analysts 28.57%
Hold
3 analysts 42.86%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their HALO stock forecasts and price targets.

HALO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-10-20
lockedlocked$00.00+00.00%2025-10-15
lockedlocked$00.00+00.00%2025-10-14
lockedlocked$00.00+00.00%2025-09-24
HC Wainwright & Co.
Top 28%
73
BuyMaintains$75.00+15.05%2025-08-06
Anonymous
Leerink Partners
SellDowngrades$47.00-27.90%2025-05-13
Wells Fargo
Top 14%
87
HoldMaintains$65.00-0.29%2025-05-07

1 of 1

Forecast return on equity

Is HALO forecast to generate an efficient return?

Company
380.42%
Industry
237.05%
Market
142.96%
HALO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HALO forecast to generate an efficient return on assets?

Company
61.63%
Industry
106.32%
HALO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HALO earnings per share forecast

What is HALO's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$6.28+40.17%
Avg 2 year Forecast
$8.14+81.6%
Avg 3 year Forecast
$9.87+120.39%
HALO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HALO revenue forecast

What is HALO's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$1.3B+14.11%
Avg 2 year Forecast
$1.7B+41.52%
Avg 3 year Forecast
$1.9B+64.59%
HALO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HALO earnings growth forecast

How is HALO forecast to perform vs Biotechnology companies and vs the US market?

Company
30.24%
Industry
37.26%
Market
41%
HALO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HALO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HALO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HALO revenue growth forecast

How is HALO forecast to perform vs Biotechnology companies and vs the US market?

Company
18.28%
Industry
106.08%
Market
24.86%
HALO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HALO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HALO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HALO$65.19$76.29+17.02%Buy
CYTK$63.59$77.39+21.69%Strong Buy
RYTM$113.76$114.17+0.36%Strong Buy
CORT$73.47$135.33+84.20%Strong Buy
NUVL$99.32$122.36+23.20%Strong Buy
View Top Biotech Stocks

Halozyme Therapeutics Stock Forecast FAQ

Is Halozyme Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: HALO) stock is to Buy HALO stock.

Out of 7 analysts, 2 (28.57%) are recommending HALO as a Strong Buy, 2 (28.57%) are recommending HALO as a Buy, 3 (42.86%) are recommending HALO as a Hold, 0 (0%) are recommending HALO as a Sell, and 0 (0%) are recommending HALO as a Strong Sell.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

What is HALO's earnings growth forecast for 2025-2027?

(NASDAQ: HALO) Halozyme Therapeutics's forecast annual earnings growth rate of 30.24% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.

Halozyme Therapeutics's earnings in 2025 is $557,278,000.On average, 11 Wall Street analysts forecast HALO's earnings for 2025 to be $734,523,087, with the lowest HALO earnings forecast at $693,491,414, and the highest HALO earnings forecast at $774,958,233. On average, 10 Wall Street analysts forecast HALO's earnings for 2026 to be $951,576,893, with the lowest HALO earnings forecast at $827,604,630, and the highest HALO earnings forecast at $1,043,921,550.

In 2027, HALO is forecast to generate $1,154,875,498 in earnings, with the lowest earnings forecast at $1,025,908,786 and the highest earnings forecast at $1,262,531,004.

What is HALO's revenue growth forecast for 2025-2027?

(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 18.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.

Halozyme Therapeutics's revenue in 2025 is $1,178,672,000.On average, 11 Wall Street analysts forecast HALO's revenue for 2025 to be $157,319,270,000, with the lowest HALO revenue forecast at $149,599,514,000, and the highest HALO revenue forecast at $163,986,332,000. On average, 10 Wall Street analysts forecast HALO's revenue for 2026 to be $195,099,288,000, with the lowest HALO revenue forecast at $179,425,844,000, and the highest HALO revenue forecast at $206,561,956,000.

In 2027, HALO is forecast to generate $226,914,040,000 in revenue, with the lowest revenue forecast at $209,252,174,000 and the highest revenue forecast at $246,330,396,000.

What is HALO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: HALO) forecast ROA is 61.63%, which is lower than the forecast US Biotechnology industry average of 106.32%.

What is HALO's Price Target?

According to 7 Wall Street analysts that have issued a 1 year HALO price target, the average HALO price target is $76.29, with the highest HALO stock price forecast at $90.00 and the lowest HALO stock price forecast at $65.00.

On average, Wall Street analysts predict that Halozyme Therapeutics's share price could reach $76.29 by Oct 27, 2026. The average Halozyme Therapeutics stock price prediction forecasts a potential upside of 17.02% from the current HALO share price of $65.19.

What is HALO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: HALO) Halozyme Therapeutics's current Earnings Per Share (EPS) is $4.48. On average, analysts forecast that HALO's EPS will be $6.28 for 2025, with the lowest EPS forecast at $5.93, and the highest EPS forecast at $6.63. On average, analysts forecast that HALO's EPS will be $8.14 for 2026, with the lowest EPS forecast at $7.08, and the highest EPS forecast at $8.93. In 2027, HALO's EPS is forecast to hit $9.87 (min: $8.77, max: $10.79).

What is HALO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: HALO) forecast ROE is 380.42%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.